Lausanne, Switzerland, October 22, 2018 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical aggregation with a ample activity focused on neurodegenerative diseases, today appear that Dr. Andreas Muhs, Chief Scientific Officer, will booty a medical leave of absence, starting immediately. During the leave of absence, AC Immune’s analysis aggregation will be led by Dr. David Lowe on an acting basis. Dr. Lowe has served as AC Immune’s Deputy Chief Scientific Officer and added afresh as Innovation Fellow back January 2014. While he is on medical leave, Dr. Muhs will break complex with AC Immune’s analysis aggregation to the admeasurement practical, and he will re-assume his role as anon as he has recovered.
About AC ImmuneAC Immune is a clinical-stage Swiss-based biopharmaceutical company, listed on Nasdaq, which aims to become a all-around baton in attention anesthetic for neurodegenerative diseases. The Aggregation designs, discovers and develops ameliorative as able-bodied as analytic articles advised to anticipate and adapt diseases acquired by misfolding proteins. AC Immune’s two proprietary technology platforms actualize antibodies, baby molecules and vaccines advised to abode a ample spectrum of neurodegenerative indications, such as Alzheimer’s ache (AD). The Company’s activity appearance nine ameliorative and three analytic artefact candidates – with bristles artefact candidates currently in analytic trials. The best avant-garde of these is crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibiotic that targets monomeric and aggregated forms of amyloid-ß, with accomplished affection for neurotoxic oligomers. Crenezumab is currently in two Phase 3 analytic studies for AD, beneath a all-around affairs conducted by the accord accomplice Roche/Genentech. Added collaborations accommodate Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Es Bio-Technology.
Forward attractive statementsThis columnist absolution contains statements that aggregate “forward-looking statements” aural the acceptation of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Advanced statements are statements added than absolute actuality and may accommodate statements that abode approaching operating, banking or business achievement or AC Immune’s strategies or expectations. In some cases, you can analyze these statements by advanced words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and added commensurable terminology. Advanced statements are based on management’s accepted expectations and behavior and absorb cogent risks and uncertainties that could account absolute results, developments and business decisions to alter materially from those advised by these statements. These risks and uncertainties accommodate those declared beneath the captions “Item 3. Key Advice – Risk Factors” and “Item 5. Operating and Banking Review and Prospects” in AC Immune’s Annual Report on Form 20-F and added filings with the Securities and Exchange Commission. Advanced statements allege alone as of the date they are made, and AC Immune does not undertake any obligation to amend them in ablaze of new information, approaching developments or otherwise, except as may be appropriate beneath applicative law. All advanced statements are able in their absoluteness by this cautionary statement.
For added information, amuse contact:
Why You Should Not Go To Leave Of Absence Form | Leave Of Absence Form – leave of absence form
| Allowed to be able to our blog, in this occasion I will show you regarding leave of absence form